Synopsis of recent research by authors named "Jenny L Craigen"
Jenny L Craigen's recent research primarily focuses on the development and validation of bioanalytical methods for monoclonal antibodies, including the ELISA method for quantifying HMBD-001, an anti-HER3 antibody, in human serum as published in Bioanalysis in 2022.
The studies also encompass the safety and pharmacokinetics of anti-IL-7 receptor monoclonal antibodies, evaluating their role in modulating T-cell activity related to autoimmune diseases, as shown in her 2019 publication in Br J Clin Pharmacol.
Additionally, Craigen has explored B-cell maturation antigen (BCMA) as a target for antibody-drug conjugates in multiple myeloma, demonstrating clinical potential and therapeutic implications through various studies, including a 2016 article in Br J Haematol.
